Aqara Previews New Devices for 2023
5.1.2023 17:00:00 EET | Business Wire | Press release
Aqara, a leading provider of smart home products, is set to expand its product portfolio in 2023 with the addition of innovative sensors, smart door locks, video doorbells and LED strips. Committed to providing seamless connected home experiences to millions of global users, Aqara continues to enrich its offerings with latest smart home technologies and new device types.
Video Doorbell G4 is complementary to Aqara’s indoor home cameras, and together these cameras help users to keep an eye on their homes, families and visitors anytime, anywhere. This doorbell allows highly flexible installation as it can be battery-powered or wired for continuous power. It not only supports HomeKit Secure Video and local streaming to Amazon and Google smart displays, but it will also work with Matter after the Matter specification for cameras is ready. The G4 features local, AI-enabled facial recognition, which can trigger different automations depending on the person, and the device also includes both the 7-day free cloud storage and the optional local storage via a microSD card.
Presence Sensor FP2 is a revolutionary addition to the Company’s wide-ranged sensor lineup. Based on the millimeter wave (mmWave) radar technology, the FP2 detects human presence even when the person is sitting still. It enables zone positioning, which allows users to define different zones within a room such as the bed, the dresser, or the sofa area, and the presence in each of these individual zone can trigger different automations for a more customized experience. Other features include multi-person detection, fall-detection and a built-in light sensor.
Smart Lock U100 is the first deadbolt lock from Aqara, offering a secure and convenient home access solution that can be seamlessly integrated into modern smart homes. The U100 lock is one of the few smart locks in the market that is compatible with HomeKit and supports the home key feature in Apple Wallet. Other access authentication options include fingerprints, passwords, Aqara Home app, NFC cards, and mechanical keys. Based on the Zigbee protocol, the U100 supports Matter via a compatible Aqara hub.
LED Strip T1 is a multipurpose RGB CCT lightstrip that is intended to enrich smart lighting experiences for Aqara users. It produces up to 16 million vibrant colors and tunable white light, and is addressable with gradient effects. HomeKit, Alexa and Google Home are supported, and Matter support via a compatible Aqara hub is expected to be added after its launch. The LED strip is Zigbee-based which means lower power consumption as well as less congested home Wi-Fi network, and it also serves as a repeater that enhances the Zigbee network.
These devices from Aqara will become available for purchase in the following months. For more information of these products, please check a demonstrative video here.
Committed to enabling seamless user experiences, Aqara has been working to integrate Matter into its existing and new devices. In 2023 new OTA updates will be pushed to Aqara hubs - beginning from the M2 - so that they can serve as Matter bridges and connect Aqara Zigbee devices to Matter. Moreover, the Company also confirmed a new lineup of Thread-based devices with native Matter support this year, including the Door and Window Sensor P2 and the Motion and Light Sensor P2 which are expected to hit the market in the coming months. As part of the ongoing partnerships with Aqara, both Google and Samsung are featuring these new sensors on respective booths at CES 2023, along with other Aqara devices including the Hub M2 as a Matter bridge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005437/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom